Cohance Lifesciences Limited special call summary

Special call of 28 Oct 2025, summarised by AI from the filing.

Cohance MD Dr. Prasada Raju resigns; board approves new structure with three business CEOs, reiterates US$1 billion vision by 2030.

Key takeaways

1. Leadership change Dr. Prasada Raju resigned as Managing Director; board approved revised structure with three business CEOs reporting to Executive Chairman.
2. Vision Management reiterated vision of a US$1 billion business by 2030, with significant portion from CDMO.
3. Phase 3 order A large Japanese customer confirmed its Phase 3 order, one of four Phase 3 commercialization products expected.
4. Surya unit Surya oligonucleotide unit completed equipment validation and remains on track for commissioning in Q4.
5. Risk Senior-level churn and cultural transition as six entities merge; new hires may cause minor short-term cost impact.

Original filing on BSE

Cohance Lifesciences Limited Q1 FY27 results

As filed: Revenue ₹422 cr (−23% year on year), EBITDA ₹1.2 cr (−99% year on year), PAT −₹45.2 cr (−198% year on year), EBITDA margin 0.3% (−1,000 bps).

The Q1 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

• Q4 FY26: Revenue ₹619 cr (+54% year on year), EBITDA ₹98.7 cr (+33% year on year), PAT ₹8.3 cr (−30% year on year), EBITDA margin 15.9% (−247 bps). Score 55 of 100, In line with trend. EBITDA margin fell 247 bps year on year. Tax rate 58%. Not enough history for a trend yet: scored on growth alone. Profit fell 20% from last quarter. Share price after the results: −12.6% in 30 days (Nifty 500: −0.8%).
• Q3 FY26: Revenue ₹482 cr, EBITDA ₹103 cr, PAT ₹47.3 cr, EBITDA margin 21.3%. Not scored. No result for the same quarter last year. Share price after the results: −15.6% in 29 days (Nifty 500: −9.6%).
• H1 FY26: Revenue ₹981 cr, EBITDA ₹236 cr, PAT ₹147 cr, EBITDA margin 24.1%. Not scored. No result for the same half-year last year. Share price after the results: −22.3% in 30 days (Nifty 500: −0.5%).
• Q1 FY26: Revenue ₹484 cr, EBITDA ₹104 cr, PAT ₹53.0 cr, EBITDA margin 21.5%. Not scored. No result for the same quarter last year. Share price after the results: −0.6% in 30 days (Nifty 500: +2.2%).
• Q4 FY25: Revenue ₹330 cr, EBITDA ₹66.0 cr, PAT ₹44.0 cr, EBITDA margin 20.0%. Not scored. No result for the same quarter last year. Share price after the results: −14.9% in 30 days (Nifty 500: +3.7%).

Past price moves after results do not indicate future moves. Not a recommendation.

Cohance Lifesciences Limited earnings call, investor presentation and press release summaries

• Q1 FY27: Earnings call (5 Aug 2026)
• Q4 FY26: Earnings call (12 May 2026)
• Q3 FY26: Earnings call (12 Feb 2026), Results deck (12 Feb 2026)
• Q2 FY26: Earnings call (12 Nov 2025), Results deck (12 Nov 2025)
• Q1 FY26: Earnings call (13 Aug 2025)
• Q4 FY25: Earnings call (28 May 2025), Results deck (28 May 2025)
• Other events: Special call (28 Oct 2025)